UA77642C2 - Human hybrid cell for expression of gene of mammals, human cell line hkb11, method for producing hybrid human cells suitable for expression of heterologic protein - Google Patents
Human hybrid cell for expression of gene of mammals, human cell line hkb11, method for producing hybrid human cells suitable for expression of heterologic protein Download PDFInfo
- Publication number
- UA77642C2 UA77642C2 UA2001074776A UA2001074776A UA77642C2 UA 77642 C2 UA77642 C2 UA 77642C2 UA 2001074776 A UA2001074776 A UA 2001074776A UA 2001074776 A UA2001074776 A UA 2001074776A UA 77642 C2 UA77642 C2 UA 77642C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cells
- cell
- human
- protein
- cell line
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 53
- 230000014509 gene expression Effects 0.000 title claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 title claims description 42
- 210000005260 human cell Anatomy 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 210000004754 hybrid cell Anatomy 0.000 title abstract description 18
- 241000124008 Mammalia Species 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 199
- 210000003292 kidney cell Anatomy 0.000 claims abstract description 14
- 208000011691 Burkitt lymphomas Diseases 0.000 claims abstract description 13
- 230000004927 fusion Effects 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000013595 glycosylation Effects 0.000 claims description 7
- 238000006206 glycosylation reaction Methods 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 3
- 108090000144 Human Proteins Proteins 0.000 claims description 2
- 102000003839 Human Proteins Human genes 0.000 claims description 2
- 238000001890 transfection Methods 0.000 abstract description 12
- 238000004114 suspension culture Methods 0.000 abstract description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 3
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 3
- 102000018358 immunoglobulin Human genes 0.000 abstract description 3
- 102000004877 Insulin Human genes 0.000 abstract description 2
- 108090001061 Insulin Proteins 0.000 abstract description 2
- 229940125396 insulin Drugs 0.000 abstract description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 230000028327 secretion Effects 0.000 description 14
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 238000010367 cloning Methods 0.000 description 6
- 238000011330 nucleic acid test Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 230000000394 mitotic effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101150004533 EBM gene Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 101150072488 Nsun4 gene Proteins 0.000 description 1
- 108010046016 Peanut Agglutinin Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/209,920 US6136599A (en) | 1998-12-10 | 1998-12-10 | Human hybrid host cell for mammalian gene expression |
| PCT/US1999/029332 WO2000034462A1 (en) | 1998-12-10 | 1999-12-08 | Human hybrid host cell for mammalian gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA77642C2 true UA77642C2 (en) | 2007-01-15 |
Family
ID=22780882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001074776A UA77642C2 (en) | 1998-12-10 | 1999-08-12 | Human hybrid cell for expression of gene of mammals, human cell line hkb11, method for producing hybrid human cells suitable for expression of heterologic protein |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6136599A (es) |
| EP (1) | EP1137768B1 (es) |
| JP (3) | JP4332300B2 (es) |
| KR (1) | KR100627753B1 (es) |
| CN (1) | CN1230532C (es) |
| AT (1) | ATE306547T1 (es) |
| AU (1) | AU757188B2 (es) |
| BG (1) | BG65263B1 (es) |
| BR (1) | BRPI9916095B8 (es) |
| CA (1) | CA2353698C (es) |
| CU (2) | CU23382A3 (es) |
| CZ (1) | CZ302677B6 (es) |
| DE (1) | DE69927707T2 (es) |
| DK (1) | DK1137768T3 (es) |
| ES (1) | ES2249929T3 (es) |
| HU (1) | HU229775B1 (es) |
| ID (1) | ID30448A (es) |
| IL (2) | IL143351A0 (es) |
| NO (1) | NO330548B1 (es) |
| PL (1) | PL205549B1 (es) |
| RO (1) | RO121563B1 (es) |
| RU (1) | RU2228355C2 (es) |
| SI (1) | SI20693B (es) |
| SK (1) | SK287888B6 (es) |
| TR (1) | TR200101642T2 (es) |
| UA (1) | UA77642C2 (es) |
| WO (1) | WO2000034462A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| US6136599A (en) * | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
| US6348192B1 (en) * | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| US20040235715A1 (en) * | 1999-11-12 | 2004-11-25 | Bayer Corporation | Method of producing glycosylated bikunin |
| US6569657B1 (en) * | 2000-06-27 | 2003-05-27 | Millennium Pharmaceuticals, Inc. | 32140, a novel human aldehyde dehydrogenase and uses therefor |
| US7094587B2 (en) * | 2000-06-27 | 2006-08-22 | Millennium Pharmaceuticals, Inc. | 16002 Molecules and uses therefor |
| MY139948A (en) * | 2000-09-28 | 2009-11-30 | Bayer Corp | Enhanced transfection system |
| US7723102B2 (en) * | 2000-09-28 | 2010-05-25 | Bayer Corporation | Enhanced transfection system |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| KR100496861B1 (ko) | 2002-09-26 | 2005-06-22 | 삼성전자주식회사 | 하나의 핸들러에 2개 이상의 테스트 보드를 갖는 테스트장비 및 그 테스트 방법 |
| AU2003298816C1 (en) | 2002-12-02 | 2010-12-16 | Amgen Fremont, Inc. | Antibodies directed to Tumor Necrosis Factor and uses thereof |
| US7244616B2 (en) | 2003-06-27 | 2007-07-17 | Bayer Pharmaceuticals Corporation | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
| HUE033776T2 (en) | 2004-11-12 | 2018-01-29 | Bayer Healthcare Llc | FVIII site-specific modification |
| KR20100040840A (ko) | 2007-06-06 | 2010-04-21 | 도만티스 리미티드 | 폴리펩티드，항체 가변 도메인 및 길항제 |
| CA2720610C (en) | 2008-04-07 | 2016-08-23 | Bayer Healthcare Llc | Methods of recombinant production of glycoproteins |
| KR101005967B1 (ko) * | 2008-04-12 | 2011-01-05 | (주)셀트리온 | 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포 |
| US9090948B2 (en) | 2008-09-30 | 2015-07-28 | Abbott Molecular Inc. | Primers and probes for detecting human papillomavirus and human beta globin sequences in test samples |
| DK2440653T3 (en) * | 2009-06-10 | 2019-03-18 | Bts Res International Pty Ltd | Methods for generating hybrid / chimeric cells and their applications |
| US11401514B2 (en) | 2016-07-19 | 2022-08-02 | Brandeis University | Compositions and methods for identifying RNA binding polypeptide targets |
| CN112118869B (zh) | 2018-05-16 | 2024-10-25 | 莫佛塞斯公司 | 靶向糖蛋白vi的抗体 |
| WO2020182974A1 (en) | 2019-03-14 | 2020-09-17 | Morphosys Ag | Antibodies targeting c5ar |
| JP2022543522A (ja) * | 2019-06-10 | 2022-10-13 | チョー プラス インコーポレイティド | タンパク質ベースの医薬品の高レベル生産のための細胞株 |
| US20230357398A1 (en) | 2020-09-24 | 2023-11-09 | Morphosys Ag | Novel human antibodies binding to human cd3 epsilon |
| CN113604425B (zh) * | 2021-06-22 | 2022-10-18 | 中山康天晟合生物技术有限公司 | 一种适应无血清培养基环境的wayne293 lvpro细胞及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6045849B2 (ja) * | 1980-08-25 | 1985-10-12 | 林原 健 | ヒトエリトロポエチンの製造方法 |
| US6136599A (en) * | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
-
1998
- 1998-12-10 US US09/209,920 patent/US6136599A/en not_active Expired - Lifetime
-
1999
- 1999-08-12 UA UA2001074776A patent/UA77642C2/uk unknown
- 1999-12-08 TR TR2001/01642T patent/TR200101642T2/xx unknown
- 1999-12-08 SK SK791-2001A patent/SK287888B6/sk not_active IP Right Cessation
- 1999-12-08 CZ CZ20012023A patent/CZ302677B6/cs not_active IP Right Cessation
- 1999-12-08 AT AT99963067T patent/ATE306547T1/de active
- 1999-12-08 PL PL349625A patent/PL205549B1/pl unknown
- 1999-12-08 KR KR1020017007224A patent/KR100627753B1/ko active IP Right Grant
- 1999-12-08 ES ES99963067T patent/ES2249929T3/es not_active Expired - Lifetime
- 1999-12-08 EP EP99963067A patent/EP1137768B1/en not_active Expired - Lifetime
- 1999-12-08 RO ROA200100648A patent/RO121563B1/ro unknown
- 1999-12-08 BR BRPI9916095A patent/BRPI9916095B8/pt not_active IP Right Cessation
- 1999-12-08 CN CNB998142999A patent/CN1230532C/zh not_active Expired - Lifetime
- 1999-12-08 WO PCT/US1999/029332 patent/WO2000034462A1/en active IP Right Grant
- 1999-12-08 ID IDW00200101235A patent/ID30448A/id unknown
- 1999-12-08 JP JP2000586896A patent/JP4332300B2/ja not_active Expired - Lifetime
- 1999-12-08 DE DE69927707T patent/DE69927707T2/de not_active Expired - Lifetime
- 1999-12-08 IL IL14335199A patent/IL143351A0/xx unknown
- 1999-12-08 DK DK99963067T patent/DK1137768T3/da active
- 1999-12-08 AU AU19383/00A patent/AU757188B2/en not_active Expired
- 1999-12-08 RU RU2001119161/13A patent/RU2228355C2/ru active
- 1999-12-08 SI SI9920096A patent/SI20693B/sl active Search and Examination
- 1999-12-08 HU HU0104681A patent/HU229775B1/hu unknown
- 1999-12-08 CA CA2353698A patent/CA2353698C/en not_active Expired - Lifetime
-
2001
- 2001-05-24 IL IL143351A patent/IL143351A/en not_active IP Right Cessation
- 2001-06-06 BG BG105566A patent/BG65263B1/bg unknown
- 2001-06-07 NO NO20012806A patent/NO330548B1/no not_active IP Right Cessation
- 2001-06-07 CU CU20010130A patent/CU23382A3/es not_active IP Right Cessation
-
2002
- 2002-08-26 CU CU20020182A patent/CU23238A1/es unknown
-
2009
- 2009-03-06 JP JP2009053279A patent/JP5508740B2/ja not_active Expired - Lifetime
-
2014
- 2014-02-24 JP JP2014032748A patent/JP5826311B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA77642C2 (en) | Human hybrid cell for expression of gene of mammals, human cell line hkb11, method for producing hybrid human cells suitable for expression of heterologic protein | |
| RU2266325C2 (ru) | Среда для культивирования клеток без белков и без сыворотки | |
| RU2249041C2 (ru) | Способ получения и выделения белка, обладающего активностью фактора viii, линия клеток нкв, экспрессирующая белок, обладающий активностью фактора viii (варианты) | |
| US8361790B2 (en) | Human host cell for producing recombinant proteins with high quality and quantity | |
| AU600481B2 (en) | Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same | |
| JP3415840B2 (ja) | 外来蛋白質の産生方法 | |
| MXPA01005783A (es) | Celula huesped hibrida de humano para expresion de gen de mamifero | |
| Kreuzburg-Duffy et al. | Establishment and characterization of murine macrophage-like cell lines following transformation with simian virus 40 DNA deleted at the origin of replication | |
| JP2960552B2 (ja) | 動物細胞の育種方法 | |
| JP3084030B2 (ja) | 新規ハイブリドーマ | |
| SU1495375A1 (ru) | Штамм культивируемых клеток гепатокарциномы человека, дефектный по тимидинкиназе дл гибридизации и трансфекции | |
| KR20220024478A (ko) | 단백질 기반 의약들 (protein-based pharmaceuticals) 의 고 수준 생산을 위한 세포주들 (cell lines) | |
| Hosoi et al. | A human-mouse hybrid cell line expressing both human leukocyte and histocompatibility-2 antigens | |
| MXPA98003051A (es) | Preparacion de factor viii recombinante en un medio libre de proteinas |